daklinza

Daklinza, as a response to hepatitis (austrila) The tool was created daklinza corporation Bristol Myers Squibb and was approved for use in Japan, Canada, Europe, the United States. Its main purpose - combating hepatitis C in combination therapy with other drugs. Assign daklinzu and requiring recovery of liver function abnormalities after suffering a hepatitis.Pharmacokinetics: the medicine contained blocker viral protein NS 5A. It does not allow the virus to penetrate from already infected cells through the blood healthy. Thus it is prevented the spread of disease in the body, and the new cell are not affected infection.It is approved in Japan as the first means without interferon therapy in the treatment of chronic hepatitis type C. Satisfactory results were obtained in the treatment of patients with cirrhosis.Clinical studies have demonstrated efficacy for 87.7 percent of the patients of the drug daklinza » . Price it is formed taking into account the cost of innovative production and growing demand.The drug is intended only for adults. According to Japanese researchers at the University of Hiroshima, to buy medicine daklinza recommend older patients, because for them the traditional treatment is ineffective.